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Abstract
Purpose: The aim of this study was to assess the potential of pre-treatment cell kinetic parameters to predict outcome in head and neck
cancer patients treated by conventional radiotherapy.
Materials and methods: Data from 11 different centers were pooled. Inclusion criteria were such that the patients received radiotherapy
alone, and that the radiotherapy was given in an overall time of at least 6 weeks with a dose of at least 60 Gy. All patients received a tracer
dose of either iododeoxyuridine (IdUrd) or bromodeoxyuridine (BrdUrd) intravenously prior to treatment and a tumor biopsy was taken
several hours later. The cell kinetic parameters labeling index (LI), DNA synthesis time (Ts) and potential doubling time (Tpot) were
subsequently calculated from ¯ow cytometry data, obtained on the biopsies using antibodies against I/BrdUrd incorporated into DNA. Each
center carried out their own ¯ow cytometry analysis.
Results: From the 11 centers, a total of 476 patients conforming to the inclusion criteria were analyzed. Median values for overall time and
total dose were 49 days and 69 Gy, respectively. Fifty one percent of patients had local recurrences and 53% patients had died, the majority
from their disease. Median follow-up was 20 months; being 30 months for surviving patients. Multivariate analysis revealed that T-stage,
maximum tumor diameter, differentiation grade, N-stage, tumor localization and overall time correlated with locoregional control, in
decreasing order of signi®cance. For the cell kinetic parameters, univariate analysis showed that only LI was signi®cantly associated
with local control (P  0:02), with higher values correlating with a worse outcome. Ts showed some evidence that patients with longer
values did worse, but this was not signi®cant (P  0:06). Tpot showed no trend (P  0:8). When assessing survival in a univariate analysis,
neither LI nor Tpot associated with outcome (P  0:4, 0.4, respectively). Surprisingly, Ts did correlate with survival, with longer values
being worse (P  0:02). In the multivariate analysis of local control, LI lost its signi®cance (P  0:16).
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Conclusions: The only pretreatment kinetic parameter for which some evidence was found for an association with local control (the best
end-point for testing the present hypothesis) was LI, not Tpot, and this evidence disappeared in a multivariate analysis. It therefore appears
that pretreatment cell kinetic measurements carried out using ¯ow cytometry, only provide a relatively weak predictor of outcome after
radiotherapy in head and neck cancer. q 1999 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
The analysis of causes of radiation failure in retrospective
series of patients with head and neck cancer and cervix
cancer, suggests a loss of local control as the overall treat-
ment time increases for the same total dose [1,4,22,33,
45,53]. This is attributed to tumor cell proliferation during
fractionated radiotherapy. As longer treatment times lead to
loss of local control, it has been suggested that shorter treat-
ment times could lead to an increase in local control. For
this reason, accelerated treatment regimens have and are
being designed [28,30,32,35,38,41]. However, these treat-
ments cause severe acute reactions. Due to this, lower total
doses are sometimes given. Slowly proliferating tumors
may therefore do worse when treated with accelerated sche-
dules compared with conventional schedules. In addition, it
is not desirable to subject all patients to the intense acute
reactions of the accelerated schedules. It would thus be
useful to predict which tumors could show rapid prolifera-
tion during treatment and would be likely to bene®t from
accelerated radiotherapy.
The median potential doubling times (Tpot), determined
in tumors before treatment, seem to be similar to the average
values of effective doubling times (Teff) which actually take
place during treatment as a response to therapy-induced cell
depletion. The cell birth rate and therefore, the potential
doubling time (Tpot), can be calculated knowing the label-
ing index (LI; proportion cells incorporating the DNA
precursor) and Ts (the DNA synthesis time). Tpot is de®ned
as the time within which the cell population of a tumor
would double if there were no cell loss [42]. The hypothesis
is thus that Tpot measured before treatment may correlate
with Teff during treatment.
With the development of antibodies to DNA-incorporated
thymidine analogues iodo- and bromo-deoxyuridine, ¯ow
cytometry could be used to more rapidly and more quanti-
tatively assess proliferation [15,16,23]. An added advantage
is that these methods could be applied after in vivo labeling
of the patient with the analogue, avoiding potential in vitro
artifacts. Several studies have employed such methods to
assess the predictive value of pre-treatment cell kinetic
parameters after radiotherapy [2,3,5,6,11,14,31,34,43,
47,54]. Results have been variable, some showing positive
association with outcome [3,5,14,47,54], and some not
[11,18,31,34,43]. Almost all the studies have included rela-
tively few patients, limiting their power.
The aim of the present study was to combine the data
from many of these trials, in order to better assess the
value of cell kinetic measurements by increasing the statis-
tical power of the analysis. The majority of reported studies
had been carried out in head and neck cancer and many for
radiotherapy alone. This paper reports on the pooled cell
kinetic data of head and neck cancer patients treated with
conventional radiotherapy from 11 centers in Europe (one
Egyptian trial was included although the measurements
were carried out in The Netherlands).
2. Materials and methods
Data on a total of 476 patients from 11 centers were
initially submitted for this analysis (Table 1). Inclusion
criteria were, no neoadjuvant chemotherapy, overall treat-
ment time longer than 39 days, total dose at least 60 Gy, and
the interval between IdUrd injection and biopsy at least 4 h.
The latter were excluded on the grounds that Ts would
probably be underestimated using the RM analysis origin-
ally proposed by Begg et al. [7]. All patients were primarily
irradiated for squamous cell carcinomas of the head and
neck with treatment schedules lasting at least 6 weeks (39
days). Median age was 59 years and sex ratio (male/female)
was 8:2. For subsequent analysis, primary tumors were clas-
si®ed into four groups: oral cavity (n  128), oropharynx
(n  211), larynx (n  86) and others (n  50). Other
tumors were nasopharynx, parotid, lip, hypopharnyx poster-
ior wall, piriform sinus, postcricoid area and unspeci®ed.
The tumor characteristics are summarized in Table 2.
Most patients had an advanced stage (T3, T4 and/or N2,
N3 tumors) at diagnosis (n  330). The majority, i.e. 343
tumors (80%), were well to moderately differentiated. Infor-
mation on tumor size was available in 236 patients. The
median diameter of the primary tumor was 40 mm (range:
7±80 mm).
Before the start of radiotherapy, iododeoxyuridine
(IdUrd) or bromodeoxyuridine (BrdUrd) in a tracer dose
was injected intravenously and a biopsy from the primary
tumor was taken several hours later. Biopsies were ®xed in
ethanol, subsequently digested, stained for IdUrd/BrdUrd
uptake and DNA content and the suspensions acquired on
the ¯ow cytometer according to standard procedures.
Measurements were done in 9 laboratories. There was no
single center serving as a reference laboratory for quality
control and measurement checks.
The DNA index of the tumor was calculated by measur-
ing the position of the tumor G1 peak relative to the diploid
G0/G1 peak. To determine the length of the S-phase (Ts),
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the simple relative movement method (RM) based on the
average position of the labeled cells between G1 and G2 was
used [7]. Brie¯y, the analysis was done by placing compu-
ter-drawn windows around the different populations and
assuming that the RM was 0.5 at time 0. The mean red
¯uorescence (DNA content) of the labeled cells relative to
the red ¯uorescence values for G1 and G2 was ®rst deter-
mined. Ts could then be calculated knowing the time
between IdUrd administration and taking the specimen, t.
The two equations used for calculating Ts were: (1): RM
 (FL 2 FG1)/(FG2 2 FG1) and (2): Ts  0.5 t /(RM 2
0.5); where FL is the mean red ¯uorescence of IdUrd/
BrdUrd labeled cells and FG1, FG2 are the mean red ¯uor-
escence positions of the G1 and G2 cells, respectively. The
labeling index (LI) was determined as the percentage of
green labeled cells (B/IdUrd content), after correcting for
the labeled cells which had divided. The potential doubling
time (Tpot) was calculated as the ratio Ts / LI, assuming that
the age distribution factor, lambda, was unity [42]. No qual-
ity control procedures, i.e. retrospective check of ¯ow cyto-
metry dot plots, were carried out in the present study. As an
indirect measure of quality, the CV of the ®rst tumor popu-
lation and the presence of a separate G1 peak were
requested on the forms.
Two separate forms were sent to the participating centers.
On the ®rst form, data on patient characteristics (initials,
center, age, sex), tumor characteristics (TNM, histology
and maximum tumor diameter), radiotherapy speci®cations
(dose, fraction size, number of fractions per day, reasons for
interruptions, overall treatment time), cell kinetics (time
between injection of B/IdUrd and biopsy, Ts, LI and
Tpot) and limited follow up information (local control,
distant metastasis, date of last follow up, death) were
requested. On an additional form, more detailed information
on treatment and follow up (complete remission in treat-
ment ®eld, addition of neoadjuvant chemotherapy and
salvage surgery) as well as more information on the quality
of the ¯ow cytometry data (CV of the ®rst tumor population
and presence of a separate tumor G1 population) were
requested.
Patients were irradiated to a total dose of 60±88 Gy
in fractions of 1.1 (one patient) to 3 Gy (one patient) per
fraction, although the vast majority of the patients were
treated with 2 Gy fractions (499, 86.3%). To study the in¯u-
ence of dose on outcome, the normalized total dose para-
meter was used, which corrects for fractionation size
employing the linear-quadratic formalism using an alpha/
beta ratio of 10 Gy, according to the equation:
NTD  D 1 1 d=10 =1:2 1
where D is the total dose of the fractionation schedule and d
is the dose per fraction. This equation calculates the dose
equivalent of a schedule in 2 Gy fractions.
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Table 2
Tumor characteristics





Oral cavity T1 7 1 1 0 16
T2 31 5 4 2 31
T3 14 10 9 1 52
T4 14 13 8 6 47
Oropharynx T1 9 2 0 2 19
T2 30 19 19 3 33
T3 30 18 16 10 45
T4 15 10 21 6 45
Larynx T1 11 2 2 0 14
T2 22 0 0 0 21
T3 18 7 3 2 32
T4 15 2 3 0 36
Others T1 1 0 0 1 ±
T2 4 2 4 1 33
T3 4 5 2 12 56
T4 6 3 5 0 52
The overall treatment time varied between 6 and 11
weeks. Ninety patients had signi®cant interruptions (6±27
days) due to acute toxicity.
Local failure was de®ned as either (a) progression in the
irradiated area or (b) the presence of viable tumor cells in
the specimen from salvage surgery or (c) death due to tumor
without registered complete remission and without the
presence of tumor outside the irradiated volume. Time of
local failure was measured from the start of radiotherapy
until time of progression (a), salvage surgery (b) or start of
radiotherapy (c). All patients without local failure were
censored at the last date of follow-up.
Information on salvage surgery was available in 299
cases; 51 patients (17%) underwent salvage surgery after
radiotherapy. Information on the resection specimen was
recorded and in 12 of these no viable tumor was present.
For subsequent analyses, these patients were regarded as
locally controlled by radiotherapy.
2.1. Statistical methods
A stepwise procedure using Proportional Hazard regres-
sion analysis was used to identify prognostic factors with
respect to local failure. In the ®rst stage, only patient and
tumor characteristics (excluding LI, Ts and Tpot) were
considered for inclusion. In the second stage treatment
factors (including center) were added and ®nally the prog-
nostic value of LI, Ts and Tpot was tested, after controlling
for the confounding variables resulting from the ®rst two
stages. The upper limit for the P-value in order to be
included as a confounding variable was 0.15.
In all analyses, interval and ordinal variables were
considered to be linearly related to log(hazard). However,
linearity of each variable was tested at each step and if non-
linearity was present the P-value of linear plus non-linear
effects was used to decide on inclusion or not.
For variables with missing values, a dummy variable was
created. The missing values themselves were replaced by a
®xed value within the range of the original variable. When-
ever the modi®ed variable was included in the model, the
proportional hazard-analysis was strati®ed according to this
missing value indicator.
At each step, the assumption of proportional hazards was
tested by plotting the weighted Schoenfeld residuals against
time. Log-cumulative hazard plots were also made, adjusted
for the other variables as covariates in the model. If these
plots suggested a deviation from the proportionality
assumption, this was investigated further by ®tting a time-
dependent model, using a linear variable ln(time) interac-
tion.
These checks were always performed for new variables to
be entered in the model. If this was judged to be a major
prognostic variable, the same was done for the variables
already in the model. If these checks shed doubt about the
proportionality assumption, then in the next steps, these
variables were used as strati®cation variables rather than
as covariates. Only when testing the variables themselves
they were used as covariates.
As marked differences between centers existed regarding
the distribution of the cell kinetic parameters (ANOVA: LI
P , 0:01, Ts P , 0:01 and Tpot P , 0:01), these para-
meters were analyzed by strati®cation per center (Table
3). In a second step, as the difference in variance between
centers for LI and Tpot (P , 0:001) was statistically signif-
icant, these parameters were also standardized using center-
speci®c mean and SD values. The standardized parameters
then have a mean of 0 and an SD of 1 within each center.
These standardized values were subsequently used in a
second multivariate analysis.
All P-values were calculated from the proportional
hazard based Wald statistic. P-values were adjusted for
multiple comparisons only where explicitly stated. In
those cases, this was done using the procedure of Hommel.
Lifetable calculations were done using the product limit
method of Kaplan and Meier.
3. Results
3.1. Proliferation characteristics
The ¯ow cytometry parameters are summarized in Table
4. One hundred and ninety-four tumors (46.9%) were
diploid and 220 were aneuploid (53.1%); in 62 cases infor-
mation on ploidy was missing. The median DNA index
was 1.38 (range 0.85±2.9). The present data con®rm that
head and neck tumors are a relatively rapidly proliferating
group of tumors with a median Tpot of 5.1 days (range
0.8±72.9 days). The median Tpot for the diploid tumors
was 6.3 days, and for the aneuploid tumors, it was 4.1
days. The median LI was 8.85% (range 0.6±47.7%), the
median for the diploid tumors being 6% while it was
12.7% for the aneuploid tumors. The median Ts was 10.7
h (range 4.4±45.7 h), and was longer in the aneuploid
subgroup (12.4 h) compared with the diploid subgroup
(10.0 h). The more rapid apparent proliferation rate of
aneuploid tumors is probably an artifact related to the abil-
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Table 3
Cell kinetic parameters per center
Center N LI (%) Ts (h) Tpot (days)
1 45 8.6(2.1±28.0) 9.8 (6.0±30.0) 4.9 (2.1±20.8)
2 59 12.6 (2.2±22.1) 11.5 (6.3±33.2) 4.6 (1.44±14.5)
3 72 8.7 (2.6±29.9) 12.2 (7.0±39.1) 6.0 (1.7±29.2)
4 61 9.7 (0.8±24.0) 15.4 (7.7±25.9) 5.6 (1.4±70.4)
5 64 7.1 (0.8±47.7) 8.4 (4.4±21.0) 4.6 (0.8±72.9)
6 31 7.0 (1.8±38.1) 9.7 (6.1±45.7) 5.0 (1.8±19.0)
7 62 6.6 (0.6±23.8) 8.3 (5.3±23.8) 4.7 (1.2±44.4)
8 32 8.0 (1.0±12.4) 15.0 (7.5±21.0) 7.4 (5.2±17.5)
9 16 10.9 (1.4±17.1) 6.6 (4.6±14.2) 3.0 (1.6±22.5)
10 15 16.3 (7.0±39.7) 11.3 (7.6±16.3) 3.1 (0.9±5.0)
11 19 13.9 (2.8±26.2) 11.4 (5.5±20.7) 4.7 (1.4±18.1)
ity to distinguish normal and malignant cells (see Section
4). There was a statistically signi®cant difference in cell
kinetic parameters between the different centers (ANOVA,
P , 0:001 for the three cell kinetic parameters: LI, Ts and
Tpot).
We also analyzed whether there was an association
between the cell kinetic parameters, primary tumor site
and differentiation grade. Site categories were oral cavity,
oropharynx, larynx and `others'. No signi®cant differences
were found for these site categories for LI (P  0:27), Ts
(P  0:57) or Tpot (P  0:10). For differentiation grade, LI
showed the biggest differences between categories, but not
in a linear manner: mean LI values were 8.1% (`well'), 9.0%
(`moderate') and 7.4% (`poor'), giving a non-signi®cant for
the association (P  0:081). Ts and Tpot showed no signif-
icant trends with grade (P-values 0.58 and 0.16, respec-
tively).
In 319 tumors information on the CV of the ®rst tumor
peak was available. The CV varied between 1.6 and 15.1%
with a median CV of 5%. In 289 (89%) of the 319 tumors in
which this information was recorded, a separate labeled
population at the G1 position was present, indicating that
the I/BrdUrd-injection time was longer than TG2M, increas-
ing the accuracy of Ts estimations.
3.2. Locoregional control and survival
A complete regression after radiotherapy was observed
in 244 of the 413 patients on whom this information was
registered. Fifty one percent of the patients (n  240)
failed locally, and 11% (n  52) suffered from distant
metastases. The median follow up for the whole group
was 20 months. Two hundred and ®fty patients died after
a median follow up of 12 months, 80% of them of their
disease. At 60 months, the locoregional control after radio-
therapy was 41.4% (SE 2.4%). The more advanced the
primary tumor, the worse local control (P , 0:0001). N-
stage also predicted for local control (P  0:0019).
Anaplastic and poorly differentiated tumors had a signi®-
cantly better local control than moderately and well-differ-
entiated tumors (P  0:042) (Fig. 1). Fig. 1 shows
locoregional control as a function of site of the primary
tumor. Larynx tumors showed a signi®cantly better local
control than oropharynx and oral cavity tumors
(P , 0:0001). Tumor size was also signi®cantly associated
with local control, small tumors doing much better than
large tumors (P  0:0005, Fig. 1).
Locoregional control was not found to be in¯uenced by
ploidy (P  0:31). For representation in the ®gures, cell
kinetic parameters (Tpot, LI and Ts) were divided into
quartiles. For the statistical analysis, however, the cell
kinetic parameters were analyzed as continuous variables.
LI was signi®cantly associated with local control
(P  0:033), with tumors having a low LI ( , 5%) doing
signi®cantly better than tumors with a high LI ( . 15%)
(Fig. 2). Tpot was not signi®cantly associated with locor-
egional control (P  0:8, Fig. 2) and there was some
evidence for tumors with a short Ts having a better locor-
egional control (P  0:057, Fig. 2).
We also attempted to de®ne an `excellent' group from the
kinetic point of view. This included tumors which were
aneuploid, had good DNA histograms (de®ned as CVs of
the tumor G1 peak # 8%), a LI $ 1.5% and a Ts # 30 h.
This excluded measurements with very low labeling, since
both LI and Ts estimations would be unreliable. In this
`excellent' group of 134 patients, P-values for local control
in the univariate analysis were no more signi®cant than for
the whole patient group: 0.19 for LI, 0.38 for Ts and 0.51 for
Tpot.
Overall survival at 60 months was 33.4% (SE 3.1%).
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Table 4
Cell kinetic parameters
Ploidy N LI (%)a Ts (h)a Tpot (days)a
Aneuploid 220 12.7 (1.2±39.7) 12.4 (5.6±45.7) 4.1 (0.9±72.9)
Diploid 194 6.0 (0.8±47.7) 10.0 (4.4±21.6) 6.3 (0.8±70.4)
Site
Oral cavity 128 8.4 (0.8±28.0) 10.3 (5.5±39.1) 5.1 (1.3±72.9)
Oropharynx 211 8.5 (0.6±39.7) 10.9 (4.4±45.7) 5.6 (1.2±44.4)
Larynx 87 10.5 (0.8±47.7) 11.0 (4.6±25.9) 4.1 (0.8±70.4)
Others 50 10.3 (1.8±34.8) 10.8 (5.6±22.6) 4.7 (0.9±22.5)
T-stage
T1 39 9.5 (1.4±47.7) 9.8 (4.6±32.1) 6.4 (0.8±22.5)
T2 146 9.6 (0.8±25.8) 11.5 (5.3±33.2) 6.7 (1.3±70.4)
T3 162 10.4 (0.6±38.1) 12.5 (5.5±45.7) 6.6 (1.4±44.4)
T4 129 10.7 (0.8±39.7) 11.9 (4.4±39.1) 6.9 (0.9±72.9)
Grade
Well diff. 222 9.9 (0.6±39.7) 11.7 (6.0±25.9) 6.4 (0.9±44.4)
Mod. diff. 168 10.8 (0.8±47.7) 11.8 (5.3±39.1) 6.7 (0.8±72.9)
Poorly diff./anapl. 86 9.6 (0.8±38.1) 12.2 (4.4±45.7) 7.8 (1.4±70.4)
a Values are the median with the ranges in parentheses
Overall survival was signi®cantly associated with T stage
(P , 0:0001), N stage (P , 0:0001), site of the primary
tumor (P  0:0071) and tumor size (P  0:0002), but not
with differentiation grade (P  0:34).
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Fig. 1. Local control as a function of differentiation grade (upper), site of primary (middle) and maximum tumor diameter (lower). All three parameters showed
signi®cant differences in a univariate analysis as assessed by log rank trend. The data show that anaplastic tumors do better than well differentiated tumors (best
vs. worst), larynx does better than oral cavity, and larger tumors do worse. Number of events/total numbers per group for grade were: 88/175 well, 94/167
moderate, 29/79 poor, 1/7 anaplastic. For site: 76/128 oral cavity, 99/211 oropharynx, 30/86 larynx, 26/50 others. For diameter: 8=34 , 20 mm, 44/98 21±40
mm, 29/51 41±50 mm, 36=48 . 50 mm.
Overall survival was not in¯uenced by either LI
(P  0:42) or Tpot (P  0:43). Unexpectedly, a short Ts
was signi®cantly associated with a better overall survival
(P  0:016).
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Fig. 2. The in¯uence of the three cell kinetic parameters on local control: LI (upper), Ts (middle), Tpot (lower). Only LI showed a statistically signi®cant
association with local control in a univariate analysis, with low LI tumors associated with a more favorable outcome. Number of events/total numbers per group
for labeling index were: 41=104 , 5%, 80/159 5±10%, 54/116 10±15%, 56=96 $ 15%. For Ts: 71=147 , 9 h, 44/101 9±11 h, 32/71 11±13 h, 84=156 $ 13 h.
For Tpot: 51=100 , 3 days, 70/132 3±5 days, 49/106 5±7 days, 61=137 $ 7 days.
3.3. Multivariate analysis
In a multivariate analysis, the in¯uence on locoregional
control of age, sex, localization of the primary tumor, T-
stage, N-stage, maximum tumor diameter, differentiation
grade, ploidy, center, overall treatment time, NTD (normal-
ized total dose; fractionation schedule correction calculated
using and a /b value of 10 Gy), LI, Ts and Tpot were tested.
Only differentiation grade (P , 0:0001), maximum tumor
diameter (P  0:0004), T stage (P  0:0007), localization
of the primary tumor (P  0:005), overall treatment time
(P  0:04) and N-stage (P  0:02) satis®ed our inclusion
criterion (P , 0:15), (Table 5). After controlling for these
factors, none of the cell kinetic parameters (LI, Ts or Tpot)
were found to be independent predictors of local failure
(Table 6).
Since signi®cant differences were found between the
centers, not only in mean cell kinetic values, but also in
their variance (Table 3, and see Section 2), a second multi-
variate analysis was carried out with strati®cation per
center. However, this lead to the same conclusions as with
non-strati®ed data, with P-values of 0.26 for LI, 0.45 for Ts
and 0.67 for Tpot (Table 6). The signi®cant differences in
variance of the parameters justi®ed a procedure in which the
multivariate analysis was performed with the standardized
values for LI, Ts and Tpot, in which parameter values are
expressed as number of standard deviations away from the
mean for each center. With this analysis, Ts turned out to be
the most signi®cant cell kinetic parameter for predicting
local control after conventional radiotherapy, although
borderline (Table 6).
4. Discussion
The question of interest here, was whether repopulation
rates during radiotherapy could be predicted before the
start of therapy, using ¯ow cytometry and in vivo labeling
with thymidine analogs. The underlying assumption is that
rapid repopulation during radiotherapy can limit cure.
Values for effective repopulation doubling times (Teff)
during the latter part of radiotherapy in head and neck
tumors, calculated from retrospective clinical data, are of
the order of 4±5 days [20,21,53]. These are in good agree-
ment with Tpot values measured in other series
[2,6,11,14,31,34,44,48,49,54], leading to the hypothesis
that Tpot may indeed be a predictor of Teff [19], and was
the stimulus for carrying out several of the studies contribut-
ing to the present analysis. The combined results of 11
studies presented here, however, do not support this hypoth-
esis.
This multicenter analysis does not support the idea that
the potential doubling time, Tpot, can predict repopulation
during radiotherapy. However, one cannot conclude from
these data that proliferation or repopulation are not impor-
tant in determining outcome. Retrospective analyses of head
and neck tumor data show that longer overall times require
the use of higher doses to achieve the same level of local
control [1,21,45,53]. These data are subject to bias [10,17]
and should be interpreted with some caution. However,
more recent data from randomized trials of accelerated frac-
tionation [29,41], DAHANCA study of six versus ®ve frac-
tions per week [37]; Polish study of seven versus ®ve
fractions per week [36], all support this idea by clearly
showing the value of shortening the overall treatment
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Table 5







Age Per 10 years 0.99 0.88±1.10
Sex Male 1
Female 0.84 0.60±1.18




T-stage Per stage 1.34 1.13±1.57
N-stage Per stage 1.17 1.02±1.34


















Overall time Per week 1.17 1.01±1.36
Dose Per 10 gray 1.23 0.74±2.03
Cell kinetics
LI Per 10 percent 1.16 0.95±1.41
Ts Per 10 h 1.09 0.86±1.38
Tpot Per 10 days 0.96 0.77±1.20
Table 6
P-values for cell kinetic parameters for strati®ed and standardized data
against local control




time, even at the expense of reducing the total dose [41].
These results strongly suggest, although do not prove, that
repopulation is an important factor determining outcome.
There are several problems with pooling data as we have
done here. There can be marked differences between centers
in the distribution of tumor and patient characteristics (such
as tumor site, grade and stage), treatment policies, radiother-
apy procedures and ¯ow cytometry procedures. Signi®cant
differences in average values and variances for the cell
kinetic parameters between centers were indeed found. For
this reason, we also analyzed the data by treating the center as
a confounding variable, leading to both strati®ed and stan-
dardized analyses. This did not alter the basic conclusions
that none of the cell kinetic parameters was a strong predic-
tor, although it reversed the relative importance of Ts and LI
(in favor of Ts). Taking into account that nine P-values were
calculated for the kinetic parameters in the multivariate
analyses, the P-value of 0.045 should not be taken as
evidence for a prognostic value of Ts. It should also be
noted that the patient group as a whole for this study was
fairly typical for head and neck tumor patients submitted
for radiotherapy: the majority were male, most tumors
were advanced, the majority were oropharynx tumors,
followed by oral cavity and larynx. The overall locoregional
control and survival results were also consistent with
published studies. In addition, the multivariate analysis of
this group con®rmed T-stage, tumor diameter, differentiation
grade and localization of the primary tumor as signi®cant and
strong prognostic indicators. Any lack of association with
outcome is therefore, unlikely to be due to an unusual distri-
bution of patients.
The ¯ow cytometry data are also consistent with
previously published data [2,3,5,9,11,14,18,31,34,43,44,
48,49,54]. Just over half the patients were reported as
having aneuploid tumors, and the aneuploid tumors had
faster kinetics (higher LI, shorter Tpot) than the diploid
tumors, as reported in other studies [5,8,9,11,14,31,34,
47,49,54]. The latter is probably due to being able to
partially distinguish tumor and normal cells on the basis
of their DNA content, which is not possible in diploid
tumors. The slower observed kinetics in diploid tumors is
then likely to be artifactual, due to the inclusion of slowly or
non-proliferating stromal cells. We therefore also analyzed
the aneuploid tumors only, and included two quality control
criteria for the ¯ow cytometry: good labeling and reliable
DNA histograms. However, this did not increase the signif-
icance of the relationship with outcome for either LI or
Tpot. Some centers advocate measuring Tpot by combining
Ts measured ¯ow cytometrically with LI measured im-
munohistochemically (IHC) [9,31], or adding a tumor-
associated marker, such as cytokeratin to ¯ow cytometri-
cally distinguish malignant and stromal cells [26]. The
IHC approach also avoids the contaminating stroma
problem, since only tumor cells, recognized morphologi-
cally, are counted. These modi®cations were not possible
with the present analysis, however, since the majority of
centers only carried out two-color ¯ow cytometry measure-
ments. Such an approach would make the kinetic estimates
more reliable for diploid tumors, although values for aneu-
ploid tumors are unlikely to change substantially [9,31].
Since the aneuploid-only analysis did not improve associa-
tions with outcome, there remains doubt as to whether a
combined ¯ow/immunohistochemistry or cytokeratin-type
approach would improve these predictors.
The reason why Tpot fails as a predictor of repopulation
in a univariate analysis whereas LI (partially) succeeds is
not clear. It indicates that combining Ts with LI destroys
the association with outcome. This could occur if high LI
values were signi®cantly associated with long Ts values,
leaving Tpot relatively unchanged. In the present data set,
Ts was signi®cantly correlated with LI (r  0:24,
P , 0:001). This correlation may have partially contribu-
ted to the poor performance of Tpot. One possible expla-
nation is technical, i.e. in setting windows around the
labeled cell population in the ¯ow cytometry data, too
high a window would reduce the LI and at the same time
reduce the estimated Ts, due to the shape of the labeled
cloud of cells in the cytogram [25]. A second trivial expla-
nation, is that the longer the S phase the more cells will be
in S, i.e. giving a higher LI. This assumes, however, that
the growth fraction, also a determinant of LI, does not vary
markedly between tumors. A third possible explanation for
the different performances of LI and Tpot as predictors, is
that LI and Ts are totally independent predictors of
outcome (high LI bad, long Ts bad) for different reasons.
For example, a high LI may re¯ect fast repopulation and a
long Ts may be correlated with radioresistance. Cells are
often the most radioresistant in late S, and so a longer S
phase may be coupled with a greater fraction of cells in a
relatively resistant phase. These are simply speculations,
however. It is noteworthy that Ts was the only parameter
that was associated with overall survival (long Ts, worse
survival). LI, which was signi®cantly associated with local
control, lost its signi®cance for survival whereas Ts did
not, suggesting that Ts may indicate something other
than simple cell kinetic behavior. An alternative explana-
tion, which cannot be excluded without further studies, is
that this is simply a chance occurrence.
The lack of local control prediction by Tpot is at odds
with some of the individual studies, which have contributed
to this analysis. The study of Corvo et al. [13,14] showed a
signi®cant association of Tpot with local control, as did
early reports of EORTC trial 22851 [5] and the Gustave
Roussy trial [12]. The latter lost its signi®cance with longer
follow-up, however, as did the EORTC trial. This could not
be fully explained by insuf®cient follow-up in earlier
reports, such that long Tpot tumors had yet to recur (Begg
et al., in preparation). The reason for a progressive loss of
signi®cance with longer follow-up, and the addition of more
patients to the studies is therefore not clear. The median
follow-up for patients in the pooled material presented
here was 20 months, and almost 30 months for surviving
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patients, which should be long enough to assess the value of
these predictors with reasonable certainty.
The problems and potential artifacts associated with pool-
ing data from different centers should not be underestimated
[46]. At least three reports in the literature indicate that
comparing absolute values of kinetic parameters between
two laboratories, even when analyzing identical material,
is a hazardous procedure leading to signi®cant inter-labora-
tory differences [25,50,51]. Ts appears to be particularly
prone to inter-laboratory and inter-observer variability. In
the present study, nine different measurement centers
contributed data. Ideally, one center should receive and
measure all material, eliminating inter-laboratory bias, but
this was impossible here since it is a retrospective analysis.
An additional factor inherent in all such biopsy-based
analyses, is intra-tumoral heterogeneity, which limits the
accuracy of all kinetic estimates [8,24,27,39,40,52]. These
considerations should encourage caution in interpretation of
the results, and it is possible that the non-signi®cance of the
kinetic parameters as predictors could be due in part to inter-
laboratory variation.
In conclusion, the data from this multicenter analysis do
not support the use of Tpot as a predictor of outcome after
radiotherapy, although inter-laboratory variation may have
contributed to the lack of signi®cance. Using non-standar-
dized data, a high LI was weakly associated with worse
local control in univariate analysis and a long Ts was asso-
ciated with worse overall survival. Clinical data strongly
suggest that long overall treatment times are detrimental
to cure, and so, if this is indeed due to repopulation, better,
more robust predictors of repopulation need to be found, or
more accurate and reproducible ways to measure the current
predictors. In addition, repopulation rate is only one of
many factors contributing to outcome after radiotherapy
and so any cell kinetic parameter should ideally be
combined with other biological and clinical parameters, in
order to provide an accurate prediction to guide the radio-
therapist how to optimize treatment for the individual.
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